Table 3: Comparison of the antiviral activity of urea derivatives 16a,b,c-19a,b,c, 16d-18d against CV-B5, Sb-1. Data represent mean values of three independent determinations. Pleconaril was used as a positive control.
| Compounds |
Vero76 |
CV-B5 |
Sb-1 |
Ref |
| - |
aCC50 |
bEC50 |
- |
- |
| 16a |
>100 |
10 |
>100 |
[17]
|
| 16b |
>100 |
>100 |
>100 |
[17]
|
| 16c |
>100 |
53 |
>100 |
- |
| 16d |
>100 |
>100 |
>100 |
[16,25] |
| 17a |
100 |
>100 |
>100 |
[17]
|
| 17b |
>100 |
>100 |
>100 |
[17]
|
| 17c |
>100 |
6.9 |
20.5 |
- |
| 17d |
30 |
>30 |
>30 |
[16,25] |
| 18a |
>100 |
>100 |
>100 |
[17]
|
| 18b |
>100 |
>100 |
>100 |
[17]
|
| 18c |
>100 |
5.5 |
17.5 |
- |
| 18d |
90 |
>95 |
>95 |
[16,25] |
| 19a |
>100 |
16 |
>100 |
[17]
|
| 19b |
>100 |
53 |
>100 |
[17]
|
| 19c |
>100 |
>100 |
>100 |
- |
| Ref. compds |
- |
- |
- |
- |
| Pleconaril |
77±6.8 |
0.005±0.002 |
2±0.6 |
- |
aCompound concentration (µM) required to reduce the viability of mock-infected Vero76 monolayers by 50%.
bCompound concentration (µM) required to reduce the plaque number of the indicated virus by 50% in Vero76 monolayers.